The Priority Review

Tag

Flolipid

1 story

Stories

  1. Regulation

    FDA proposes withdrawal of approval for Salerno's Flolipid suspension

    The FDA's Center for Drug Evaluation and Research proposes to withdraw approval of NDA 206679 for Flolipid suspension 20 mg/5 mL and 40 mg/5 mL because Salerno Pharmaceuticals has repeatedly failed to file required annual reports. Salerno may request a hearing on the proposal.